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Abstract 23 
Bioactive glasses (BGs) and related glass-ceramic biomaterials have been used in 24 
bone tissue repair for over 30 years. Previous work in this field was comprehensively 25 
reviewed including by their inventor Larry Hench, and the key features and properties 26 
of BGs are well understood. More recently, attention has focused on their 27 
modification to further enhance the osteogenic behaviour, or further compositional 28 
changes that may introduce additional properties such as antimicrobial activity. 29 
Evidence is emerging that BGs and related glass-ceramics may be modified in such a 30 
way as to simultaneously introduce more than one desirable property. The aim of this 31 
review is therefore to consider the evidence that these more recent inorganic 32 
modifications to glass and glass-ceramic biomaterials are effective, and whether or 33 
not these new compositions represent sufficiently versatile systems to underpin the 34 
development of a new generation of truly multifunctional biomaterials to address 35 
pressing clinical needs in orthopaedic and dental surgery. Indeed, a number of 36 
classical glass compositions exhibited antimicrobial activity, however the structural 37 
design and the addition of specific ions, i.e. Ag+, Cu+, and Sr2+, increased the 38 
antimicrobial activity. 39 
  40 
 3 
 41 
1. Introduction 42 
Multiple degenerative and inflammatory joint and bone diseases affect millions of 43 
people worldwide. In fact, in 2007 the Bone and Joint Decade’s association predicted 44 
that the percentage of people over 50 years of age affected by bone diseases will 45 
double by 2020 [1, 2]. The huge increase in joint and bone implant surgeries parallels 46 
that of medical-device associated infections (MDAIs) [3-7]. Bacterial infections 47 
associated with contamination of implanted medical devices are a critical 48 
complication that often leads to the failure of the implant with significant impact 49 
concerning public health in developed countries [8-10]. Moreover, the management of 50 
MDAIs often requires the need for surgical intervention or/and prolonged usage of 51 
intravenous or oral antibiotic therapies leading to bone loss and significant morbidity 52 
resulting in severe limitations to the patients regarding normal life and wellbeing [7, 53 
11, 12]. 54 
To summarise, there is now a pressing clinical need to develop innovative 55 
biomaterials or device surfaces that provide the dual functionality of both: bone tissue 56 
regeneration and inhibition of pathogenic microorganisms. Such a technology would 57 
contribute significantly to a surgical solution to the problem of increasing infection 58 
rates in the most vulnerable patient groups. Extensive research have led to the 59 
development of bioactive glasses (BGs) and related glass-ceramics with excellent 60 
biocompatibility and bioactivity [2, 13-20]. However, clinical applications have so far 61 
been limited to what bone bonding and integration concerns. Their range of uses can 62 
be extended significantly by a better understanding of the structural role of each 63 
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component in the glass, allowing intelligent design of the glass and glass-ceramics 64 
and thus introducing multifunctionality. 65 
The purpose of this review is to determine whether or not BGs and related glass-66 
ceramic biomaterials have the potential to provide the first generation of 67 
multifunctional biomaterials for the manufacture of advanced medical devices for 68 
bone surgery in orthopaedic and dental surgery. In addition, the authors will consider 69 
how inorganic modifications to glass and glass-ceramics can be used to introduce 70 
greater multifunctionality by enhancing antibacterial properties and to create a new 71 
generation of versatile, multifunctional materials for biomedical applications. 72 
 73 
2. Bioactive glass and glass-ceramic biomaterials 74 
Since 1969, Hench [21] and their co-workers were largely responsible for the 75 
development of bioactive glasses (BGs) and study their bone bonding properties. 76 
Later, the work in this field was comprehensively reviewed by Rees Rawlings [22] in 77 
1993, which included a description of the key features and properties of BGs and their 78 
glass-ceramics derivatives. In this framework, remarkable developments in the glass 79 
and glass-ceramic biomaterials for bone and joint repair and replacement have been 80 
made in the last 5 decades. It began with the development of a “bioinert” material, 81 
only aiming to minimise the scar tissue formation at the surface of the host tissue. 82 
Then, after extensive research it evolved to a BG concept, such as Bioglass® 45S5 83 
with extraordinary interfacial bond properties between implants and bone [23]. Later, 84 
a third generation of biomaterials that aiming functional properties such as enhanced 85 
cell proliferation and osteogenic properties or even more recently the antibacterial 86 
activity, either by inorganic modifications and/or by intelligent design of the glass and 87 
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glass-ceramics [1, 16, 18, 21, 24-29]. BGs and in particular the mechanisms 88 
responsible for their behaviour in the body have been reviewed extensively by some 89 
of the leading figures in the field [30-32]. Their sections on BG science were 90 
comprehensive and the subject is therefore only covered briefly here. However, 91 
relatively little attention has been paid to the development of antimicrobial glasses, 92 
and this is therefore reviewed in far more detail in Section 3, as well as their 93 
mechanisms of action in Section 4. 94 
Glass biomaterials can predominantly be fabricated either by the traditional melt-95 
quench or sol-gel processes, where a number of simple compounds are able to mix 96 
and solidify as a glass [33-36]. The glass structure is composed of network formers 97 
(e.g. Si4+, B3+ and P3+), usually silica, which contributes to the network formation 98 
containing either intermediate oxides (e.g. Al3+, Zn2+, Mg2+) and/or network modifiers 99 
(e.g. Sr2+, Ca2+, Na+). Intermediate oxides, depending on the composition of the glass, 100 
may play a network or disrupting function, while network modifiers disrupt the 101 
network and produce non-bridging oxygen ions. 102 
A second step of controlled heat treatment is necessary to obtain glass crystallisation 103 
forming glass-ceramics [37, 38]. This second heat treatment that leads to 104 
crystallisation involves two stages, first a nucleation and then a crystal growth stage, 105 
which promote the re-arrangement of the glass structures generating a well-ordered 106 
and crystalline structure. Crystallisation can also be a key factor for the fabrication of 107 
multifunctional glass-ceramics, modulating theirs resorbability, cytotoxicity and 108 
bioactivity [20, 39-42]. However, not all glasses are able to undergo a controlled heat 109 
treatment and form glass-ceramics either because they are already too stable or too 110 
unstable and difficult to have a controlled heat treatment. Therefore, glasses and 111 
 6 
glass-ceramics possess the same building units just arranged in many different 112 
patterns, which leads to different final properties. The work in this field was 113 
comprehensively revised by Hench et al. [21, 43], Rawlings et al. [22] and Julian 114 
Jones [30]. 115 
Silicate glasses, the most used BGs, are well studied to form of a bone-like 116 
hydroxyapatite (HA) layer that is fundamental for a strong interfacial bond between 117 
the device and bone [21, 23]. The mechanism of bioactivity and bone bonding has 118 
been extensively studied in vitro (immersion in SBF) and in vivo, mainly for 45S5 119 
bioglass® and was discussed elsewhere [44, 45]. Thus, the bonding ability of glass 120 
and glass-ceramics relies in the degradation process of the biomaterials and 121 
subsequent formation of a HA layer on their surface, which mimics the mineral bone 122 
composition, bonding firmly with living bone tissue. Briefly the process follows the 123 
succeeding steps, (1) dissolution of ions from the glass into the medium, (2) reaction 124 
of dissolved Ca2+ and (PO4)
3- from the media and consequent precipitation of 125 
amorphous calcium phosphate (ACP) layer, (3) the pH unbalance and increased 126 
dissolution of ions supports the growth of ACP, and (4) ACP layer incorporates (OH)- 127 
and (CO3)2- from the media and crystallises as HA layer. Figure 1 shows a schematic 128 
of the steps involved in the formation of HA, as well as SEM micrographs of HA 129 
structures formed on the surface of glass particles after immersion of SBF. 130 
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Figure 1 - (a) Schematic view of the steps involved in the formation of a HA layer. (b) 132 
SEM micrographs of BG particles after immersion in SBF showing the apatite-like 133 
structures formed at their surface (5000x magnification); (c) detail of apatite-like 134 
surface layer (100000x magnification). The red arrows indicate the glass particles and 135 
yellow arrows indicate the formed apatite-like structures. 136 
The silicate-based glasses and glass-ceramics are commonly associated with slow 137 
degradation rates and incomplete conversion to HA. This might result in a mismatch 138 
of the degradation rate with the rate of new tissue formation and the presence of long-139 
term unconverted glass and glass-ceramics in the human body [45-48]. More recently, 140 
borate- and borosilicate-based glasses have been used with great potential to 141 
overcome the drawbacks of the silicate-based glasses [48-50]. Due to their lower 142 
chemical durability, borate and borosilicate bioactive (BBGs) glasses present 143 
increased biodegradation and more complete conversion to HA. BBGs offer a more 144 
controlled dissolution rate that triggers a range of biological responses required for 145 
the final biomaterial [51]. Furthermore, boron is associated with bone healing, 146 
stimulating bone formation and with the increase in bone resistance to fractures [52-147 
54]. Thereby, the compositional flexibility is at most importance while designing 148 
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glasses or glass-ceramics. A number of parameters might influence the design of the 149 
BGs. As already been shown a controlled release of ions promotes HA formation 150 
leading to an osteointegration, while stimulating osteogenic functions of the 151 
surrounding cells [52, 55]. For instance, Maeno et al and Santocildes-Romero et al 152 
[56, 57] showed that ions such as Ca2+ and Sr2+ influenced both HA deposition and 153 
osteogenic behaviour of cells [56, 57]. In fact, Santocildes-Romero et al. [57] 154 
reported a strong evidence for upregulation of key genes as a mechanism for 155 
osteoconductivity or osseoinductivity in both conventional 45S5 and Sr-substituted 156 
BGs, which supported previously postulated theories for bioactivity of glasses. 157 
Specific trace amount of component ions (e.g. Ag+, Cu+, Mg2+, Ca2+, Sr2+ and Zn2+) 158 
incorporated and released in a controlled manner can trigger a range of different 159 
biological responses, such as bioactivity, osteogenic activity or/and antimicrobial 160 
activity [26, 55, 58-60]. 161 
Another important issue to consider while designing glass and glass-ceramic 162 
formulation are the external local environment generated by the degradation of the 163 
biomaterials that might be too harsh for the host tissue. Often, glasses are associated 164 
to a certain degree of cytotoxicity, which can potentially affect host cell viability in 165 
areas surrounding the medical device [20, 39]. For instance, large increases of pH can 166 
induce adverse tissue responses, while the high local osmolarity variations can 167 
produce an unbalanced cellular response. Bakry et al. [61] showed that some the 168 
reported cytotoxic effects of 45S5 bioglass® were associated with the initially acidity 169 
of the local environment. In these cases it might be beneficial to use heat treatments in 170 
order to induce crystallisation of the glass phase forming a more-stable glass-ceramic, 171 
with a better controlled degradation rate [20, 37, 40, 41]. Hurrell-Gillingham et al. 172 
[41] investigated the effects of devitrification of glass-ionomer cements from SiO2-173 
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Al2O3-P2O5-CaO-CaF2 system onto a glass-ceramic improving its in vitro 174 
biocompatibility. More recently, Fernandes et al. [20] also demonstrated that a 175 
controlled crystallisation of BBGs might be used to improve the biocompatibility of 176 
these glass-ceramic systems. 177 
Glass and glass-ceramics are specific ion-containing matrices that latetly are being 178 
more often investigated not only for bone repair, but for the prevention and treatment 179 
of bone infections. As described above, they have excellent bioactive properties, 180 
strongly bonding to bone tissue through complex reactions [21] with good 181 
biocompatibility and great osteoinductive and osteoconductive properties [21, 23, 44, 182 
62]. They have been used in the form of particles, porous or dense scaffolds for 183 
orthopaedic surgery and dentistry for bone repairing [23, 30, 63]. As a matter of fact, 184 
different inorganic modifications have been introduced by several researchers in order 185 
to achieve glass and glass-ceramics (Figure 2) endowed with antibacterial properties, 186 
resulting either in intrinsic and/or enhanced antibacterial activity. Those biomaterials 187 
can be applied through a diversity of final forms depending on their application in the 188 
body. As shown in Figure 2a, glasses can either be designed with inorganic species 189 
into the bulk glass network or surface modified after glass formation. Moreover, 190 
different heating and cooling rates can be used to induce a phase separation, which 191 
can create groups of specific ionic components to be released at different rates, tuning 192 
biological response. On the other hand, glasses can be submitted to controlled thermal 193 
treatments, resulting in to a glass-ceramic (Figure 2b). Different properties can be 194 
obtained either by inducing the formation of crystalline phases in a glass matrix or by 195 
the formation of a residual glass in to the glass-ceramic matrix providing different 196 
releasing profiles, and modulating the bioactive and antimicrobial properties of the 197 
glass-ceramics 198 
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 199 
Figure 2 - Potential routes to enhance the antimicrobial properties of a) BGs and b) 200 
glass-ceramics via crystallisation of the glass phase. 201 
The following section will review the different glass and glass-ceramics currently 202 
proposed to reduce the risk of infection in bone and joint surgery, as well as the 203 
potential for these materials to be used to treat deep bone infections themselves. 204 
 205 
3. Antimicrobial glass compositions and modifications 206 
While there is undoubtedly a growing clinical need for antimicrobial devices, the 207 
regulatory environment makes it increasingly difficult to bring simple drug-device 208 
combinations to the market. Major pharmaceutical companies with the potential to 209 
make progress are also struggling to justify the development of antibiotics of last 210 
resort from an economic standpoint. The Food and Drug Administration (FDA) is 211 
approving increasingly fewer antibiotics. Statistical analysis performed by the Center 212 
for Disease Dynamics, Economics & Policy (CDDEP) highlighted that only six 213 
antibiotics were approved in the period between 2010 and 2014, 10 fewer than in the 214 
four-year period between 1983 and 1987. Actually, many of the drugs approved by 215 
FDA in the 1980s and 1990s have since been taken off the market for a variety of 216 
reasons, including: safety, efficacy or reduced of profitability [64]. Additionally, 217 
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antibiotics are not an ideal solution due to challenges in reaching the target organisms, 218 
especially when these become associated with a medical device [10, 65, 66]. Local 219 
and/or preventive treatments may therefore be a superior approach to deal with 220 
bacterial infections. Different methods of loading antibiotic into medical devices are 221 
been used for local application of antibiotic although manufactures are focusing their 222 
efforts to improve existing active ingredients instead of developing new compounds. 223 
Rahaman et al. have summarised part of the field, but they limited their review to a 224 
narrow range of papers and did not consider more detailed or complex aspects of 225 
glass design and structure properties relationships [67].  226 
Glass and glass-ceramic biomaterials have been studied for more than 50 years 227 
resulting in the development of hundreds of different formulations. The controlled 228 
design or/and modification of the glass and glass-ceramics is the key factor to impart 229 
a suitable multifunctionality to the medical device [21, 26, 29, 68-70]. They are 230 
design to have suitable osteointegration and have been demonstrating antibacterial 231 
activity when specifically assessed [26, 71-74]. Allan et al. [71] tested with success 232 
the use of 45S5 bioglass® to inhibit several oral bacteria (including Streptococcus 233 
sanguis, Streptococcus mutans and Actinomyces viscosus) while repairing periodontal 234 
defects. This antibacterial activity has been generally attributed to the release of ions 235 
to the reaction media and their effect in the local physiological environment (e.g. pH, 236 
osmolarity). Zhang et al. [72] have demonstrated that BGs without any special 237 
bactericidal components exhibited antibacterial activity towards a large selection of 238 
bacteria in a concentration-dependent manner. The authors correlated this activity 239 
with the increase of pH and the concentration of alkali ions. In this study the glass 240 
S53P4 inhibited the proliferation of all the tested bacteria, e.g. Escherichia coli, 241 
Pseudomonas aeruginosa, Moraxella catarrhalis, Enterococcus faecalis, 242 
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Staphylococcus epidermidis. Moya et al. [75, 76] studied borosilicate glasses (SiO2–243 
Na2O–CaO–B2O3 system) with a high content of calcium oxide and found that Ca2+ 244 
concentration is related with the biocidal activity against Gram-positive, and Gram-245 
negative bacteria. Several other authors also related the antibacterial effect of glass 246 
biomaterials with pH and ion concentrations [73, 77, 78]. This type of activity (based 247 
on intrinsic antibacterial properties) mainly relies on the degradation of the network 248 
and the leaching of species of the surrounding environment. Therefore, it is of most 249 
importance to fully understand the mechanisms of glass structure formation and their 250 
effect on degradation (Figure 2) to specifically design glasses towards the final 251 
application.  252 
Several pathogenic microorganisms (predominantly Staphylococcus aureus, S. 253 
epidermidis, E. coli and P. aeruginosa) have been identified at the site of 254 
approximately 90% of all implants, and many of these microorganisms present 255 
resistance to antibiotics [9, 79, 80]. The critical complications of bacterial 256 
contamination are mostly related with the adhesion of bacteria to the medical device, 257 
which produce an hydrated extracellular matrix (ECM) generating biofilms [81-83]. 258 
These multifaceted structure made from microorganisms and ECM is capable of 259 
resisting antibiotics and antibacterial agents, and are at the root of many persistent and 260 
chronic bacterial infections [84]. Intrinsic glasses and glass-ceramics have been found 261 
to be effective against bacteria sessile communities that are at the root of many 262 
persistent and chronic infections. Allan et al. [85] showed that 45S5 bioglass® 263 
significantly lowered the viability of biofilms of S. sanguis when compared with an 264 
inert glass control. While, Batalu et al. [78] reported that although MgB2 nano or 265 
micropowders did not affected the S. aureus biofilm formation, it strongly inhibited E. 266 
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coli adhesion and viability. Once again, the authors related the activity mainly with 267 
pH and the release of boron derivatives. 268 
The intrinsic activity of glass and glass-ceramics is rarely highly specific and 269 
uniquely oriented towards prokaryotic cells. However, antibacterial glass and glass-270 
ceramics can be developed by the simple incorporation of specific ions (e.g. Ag+, 271 
Ce3+, Cu+, Zn2+, Sr2+) with known antibacterial activity. These ions can either be 272 
incorporated into the bulk network of the glasses or at the surface (Figure 2). Within 273 
the last few years, a number of glasses and glass-ceramics have been studied specially 274 
for their antibacterial properties [59, 77, 86, 87]. The majority of the studies were 275 
carried out with silver doped glasses. For instance, Bellantone et al. [86] and Ahmed 276 
et al. [77] demonstrated that silver doped glasses present not only bacteriostatic, but 277 
they also caused a rapid bactericidal action against E. coli, P. aeruginosa, and S. 278 
aureus. Bellantone et al. [86] prepared their silica-based silver containing glass via an 279 
acid-catalysed sol-gel route and observed that the dissolution profiles of Ag+ from the 280 
glasses were consistent with silver accumulation by the bacteria. While, Ahmed et al. 281 
[77] prepared phosphate-based silver containing glasses by melt-quenching and 282 
verified that the increase on antibacterial activity matched the increase in silver 283 
content in the glass formulation. 284 
Several ions referred as antibacterial agents were also studied. Brauer et al. [88] 285 
developed melt-derived BGs of calcium substituted with strontium and tested it as a 286 
strontium-releasing injectable bone cement. They demonstrated the antibacterial 287 
activity against S. aureus and S. faecalis for the treatment of osteoporosis-related 288 
vertebral compression fracture. Whereas, Mulligan et al. [87] used cooper doped 289 
glasses to eliminate S. sanguis biofilm found in the oral cavity. They prepared 290 
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phosphate-based glasses doped with increasing amounts of copper by melt-quenching 291 
with the capacity to decrease the viability of S. sanguis biofilm. However, after a time 292 
period it returned to levels similar to those of the controls. Neel et al. [89] also 293 
prepared phosphate-based glasses containing copper in the final form of fibres. Those 294 
fibres were capable to reduce the number of viable S. epidermidis attached to the 295 
fibres and in the surrounding environment. Another well know metal, Zinc, was 296 
incorporated into silica-nanoparticles prepared by sol-gel showing well defined 297 
antimicrobial activity. Halevas et al. [90] tested different concentration of 298 
incorporated zinc against S. aureus, Bacillus subtilis, Bacillus cereus, E. coli, P. 299 
aeruginosa, Xanthomonas campestris exhibiting higher activity for higher 300 
concentrations. There are other ions, such as cerium and galium that were also tested 301 
for antibacterial properties. Goh et al. [59] have tested cerium doped glasses for their 302 
antibacterial properties. They reported significant improvements regarding the 303 
antibacterial activity against E. coli of silica-based glasses with 5 mol% of Ce or 304 
higher. Valappil et al. [91] tested phosphate-based glasses doped with gallium and 305 
silver to study their combined action. They showed that the simultaneous release of 306 
Ag+ and Ga3+ from the glass reduced Porphyromonas gingivalis biofilm growth with 307 
a maximum effect after 168 h. 308 
The composition of the glass is the essence of the antibacterial properties discussed in 309 
the paper. Modulating the release rate of ions and, consequently, the osmolarity and 310 
pH at the reaction site are at the centre of the reported activity. However, there are 311 
other features such as particle size, porosity and morphology that can alter the 312 
potency of these biomaterials. It has been found that BGs release rates are directly 313 
influenced by surface area. The release of biologically relevant levels of soluble ionic 314 
depends on the particle size [92]. Mortazavi et al. [93] assessed the antibacterial effect 315 
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of BG nanoparticles obtained by sol-gel reporting that the antibacterial activity was 316 
caused by a synergetic effect of a high calcium concentration and an alkaline pH, 317 
which might have been modulated by the reduction of particle size (20 to 90 nm). 318 
Glass composition 58S showed antibacterial activity against E. coli, P. aeruginosa, 319 
and S. aureus while 63S exhibit activity only against E. coli, S. aureus and 72S didn’t 320 
show any activity. 321 
The level of ions release is directly associated to the roughness of the surface. The 322 
higher the roughness, the wider the surface area and therefore higher the release rate. 323 
Similarly, higher the porosity of the BGs, higher the surface area, which modulates 324 
the release of ions. Some other studies reported the influence of particle size and 325 
morphology of glass and glass-ceramics [72, 94]. For instance, Waltimo et al. [94] 326 
studied SiO2-Na2O-CaO-P2O5 nano BGs and the influence of their specific surface 327 
area in the release of ions and antibacterial activity. They reported that the increase of 328 
surface area induces a faster dissolution of alkaline species to the medium, increasing 329 
the pH of the medium, and therefore the antibacterial activity. The physico-chemical 330 
factors such as roughness and porosity can also influence bacteria adhesion and 331 
therefore influencing biofilm formation. The irregularities of the material surfaces 332 
normally promote bacterial adhesion, leading to biofilm accumulation whereas a 333 
smooth surface do not favour bacterial adhesion and biofilm formation [6]. 334 
The bulk materials that exert an antibacterial action in the absence of modifications 335 
can generally be described as intrinsically antibacterial. They are designed 336 
specifically to present bone integration properties, however, while not being designed 337 
as antibacterial materials they can present such activity. Whereas, enhanced glass and 338 
glass-ceramics differ from the intrinsic ones because they either have one or more 339 
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ionic species intentionally incorporated as antibacterial agents, or are loaded with 340 
bactericidal substances or coated with active functional molecules to impart a 341 
functional antibacterial activity. Table 1 summarises substituted BGs or glass-342 
ceramics that present antibacterial activity correlating them with their active 343 
components. 344 
Table 1 - Examples of BGs or glass-ceramic biomaterials that present antibacterial 345 
activity and the correlation with the factors and components responsible for that 346 
activity 347 
Active 
factor 
Glass system 
Organisms 
Ref 
Gram (-) Gram (+) 
Ag+ 
SiO2-CaO-P2O5-Ag2O 
E. coli 
- [33] 
P. aeruginosa S. aureus 
[86] 
E. coli S. aureus 
[95] 
P2O5-CaO-Na2O-Ag2O E. coli,  P. 
aeruginosa 
S. aureus [77] 
B2O3-Na2O-P2O5-Ag2O - Listeria 
monocytogenes 
[96] 
SiO2-Ag (ceramic) 
E. coli S. aureus 
[97] 
Ag2O-B2O3-SiO2-CaO 
E. coli S. aureus 
[98] 
SiO2-CaO-P2O5-Al2O3-
Na2O-K2O-Ag2O E. coli E. faecalis 
[58] 
Ag+ ; pH CaO-SiO2-Ag2O E. coli S. aureus [99] 
Ag+ ; Ga3+ 
CaO-Na2O-P2O5-Ga2O-
Ag2O 
biofilm (Streptococcus gordonii 
and P. gingivalis) 
[91] 
Ag+ ; Zn2+ 
Ceramic doped with 
Ag-Zn E. coli 
- [100] 
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Ce+ ; pH SiO2-CaO-P2O5-Ce E. coli - [59] 
Cu+ 
Na2O-CaO-P2O5-Cu - 
biofilm (S. 
sanguis) 
[87] 
Na2O-CaO-P2O5-Cu - S. epidermidis [89] 
Si4+ ; pH S53P4 E. coli - [101] 
Zn2+ 
SiO2-Zn NPs E. coli S. aureus [102] 
SiO2-Zn NPs 
E. coli, P. 
aeruginosa, X. 
campestris 
S. aureus, B. 
subtilis, B. 
cereus 
[90] 
[ions] ; pH 
45S5 bioglass® 
E. coli,  P. 
aeruginosa, 
Actinobacillus 
actinomycetemc
omitans, P. 
gingivalis, 
Fusobacterium 
nucleatum 
S. sanguis, S. 
mutans, A. 
viscosus and E. 
faecalis 
[71, 
94, 
103] 
biofilms (S. sanguis) [85] 
58S and 63S bioglass® 
E. coli, P. 
aeruginosa, 
Salmonella 
typhi 
S. aureus [93] 
S53P4 
Acinetobacter 
spp, 
Haemophilus 
influenza, 
Enterobacter 
aerogenes, M. 
catarrhalis, E. 
coli, P. 
Aeruginosa 
S. epidermidis, 
E. faecalis 
[72, 
73, 
104] 
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MgB2 E. coli S. aureus [78] 
Na2O-MgO-CaO-B2O3-
P2O3-SiO2/K2O/Al2O3 
Acinetobacter 
spp, H. 
influenza, E. 
coli, P. 
aeruginosa 
E. faecalis [72] 
Na2O-K2O-MgO-CaO-
P2O3-SiO2 
Acinetobacter 
spp, H. 
influenza, E. 
aerogenes, E. 
coli, P. 
aeruginosa 
S. epidermidis, 
E. faecalis 
[72] 
Na2O-K2O-MgO-CaO-
B2O3-P2O3-SiO2 - S. epidermidis 
[73] 
P2O5-CaO-Na2O E. coli, P. 
aeruginosa 
S. aureus [77] 
SiO2-B2O3-Na2O-
MgO/SrO P. aeruginosa S. epidermidis 
[26] 
 
SiO2-P2O5-CaO-Na2O-
SrO 
Aggregatibacter 
actinomycetemc
omitans, 
Porphyromonas 
gingivalis 
- [25] 
[Ca2+] 
SiO2-B2O3-Na2O-CaO-
K2O-Al2O3 
E. coli, P. 
aeruginosa 
S. aureus, S. 
epidermidis 
and 
Micrococcus 
luteus 
[105] 
SiO2-Na2O-CaO-P2O5-
Al2O3-
Fe2O/B2O3/K2O/MgO 
E. coli 
M. luteus, 
Candida kruse 
[76] 
SiO2-Na2O-CaO-
B2O3/K2O-Al2O3 E. coli - 
[75] 
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[Ca2+] ; pH 
SiO2-CaO-Na2O-K2O-
P2O5/MgO - S. aureus 
[74] 
[Sr2+] SiO-SrO-CaF2-MgO - S. aureus, E. 
faecalis 
[88] 
pH CaO-SiO2 
E. coli S. aureus 
[99] 
 348 
 349 
4. Mechanisms of antimicrobial activity 350 
Composition is the basis of the properties of glasses and glass-ceramics. It can 351 
modulate the rate of ions release and consequently the local osmolarity and pH, 352 
influencing the physiological conditions at the surrounding of the medical devices. 353 
Therefore, the antibacterial glasses and glass-ceramics is often engaged by their 354 
composition and dissolution properties [26, 71, 75, 85]. 355 
Recently, Echezarreta-López et al. [106] compiled from literature a large database on 356 
the production of glass biomaterials, bacterial properties and experiments using an 357 
artificial intelligence tool, named: neurofuzzy logic technology. They verified that the 358 
antibacterial properties of glass and glass-ceramics can be induced by the release of 359 
alkaline ions, particularly Ca2+ ions, and the increase of the pH of the medium. 360 
Briefly, the mechanisms of action are described in three steps: (i) release of ions that 361 
increases their (ii) osmolarity and (iii) pH at the reaction site, unbalancing the 362 
bacterial intracellular Ca2+, which results in cell membrane depolarisation and their 363 
subsequent death. Cabal et al. [105] reported that borosilicate glass-ceramics were 364 
able to inhibit bacterial growth, minimise bacterial adhesion and prevent biofilm 365 
formation by the perturbation of intracellular Ca2+ compartmentalisation, causing 366 
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cytotoxicity and resulting in either apoptotic or necrotic bacteria cell death. This work 367 
tested the borosilicate glasses against five ATCC strains (S. aureus, S. epidermidis, P. 368 
aeruginosa, E. coli and M. lutea) showing a reduction of the viability of bacteria. 369 
The antimicrobial activity is dependent on the release rate of ions in an aqueous 370 
environment. The lethal effects of those ions on bacterial cells are possibly due to 371 
damage to the bacterial cytoplasmic membrane, denaturation of proteins, or damage 372 
to the DNA. Ions release from BGs might interact with the cytoplasmic membrane, 373 
deregulating the extra- and intracellular enzymes activity. Moreover, the high pH 374 
from the ions release also alters the integrity of the cytoplasmic membrane, provoking 375 
proteins denaturation. The adjustment of intracellular pH might affect cellular 376 
functions, including the essential enzymes for cellular metabolism. 377 
However, there are several enhanced glass and glass-ceramics that have their 378 
antibacterial activity based in the use of stable metals, such as silver (between many 379 
other: Ce3+, Cu+, Zn2+, Sr2+), which are reported to present antibacterial activity [107]. 380 
BGs are used as carriers for the controlled delivery of active metals. They can be 381 
incorporated into the glass structure during fabrication and, while degrade release 382 
them at a clinically acceptable rate. In these cases, the antibacterial activity is oriented 383 
towards prokaryotic cells and it is usually specific. However, occasionally, they are 384 
associated to a certain degree of cytotoxicity towards animal cells [108]. Regarding 385 
the use of antibacterial metals, which is frequently active due to their corrosion in the 386 
physiological environment, or their leaching to surrounding medium, the high 387 
concentration of those ions might also cause local toxicity. 388 
A number of studies have been proposing possible mechanisms for antimicrobial 389 
properties of those elements, which are associated with disruption of bacteria 390 
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function, the unbalance of the electron transport, the binding to DNA or the 391 
interaction with the cell components. Even though the exact mechanism of the activity 392 
of the metal ions regarding antibacterial action is still unknown it is recognised that it 393 
relies on a combination of actions. Silver has been one of the most studied materials, 394 
and have been intentionally used in surgeries for its bactericidal properties. It acts by 395 
inactivating critical enzymes of the respiratory chain by biding to thiol groups and 396 
inducing the formation of hydroxyl radicals promoting oxidative stress [109]. 397 
However, other chemical activity, e.g. hydrogen, bonding may also be involved. In 398 
this case it inhibits the synthesis of the bacterial cell wall proteins and bacterial RNA 399 
and DNA. It has been also reported that it inhibits the metabolic pathway [109, 110]. 400 
Therefore, the activity is generally associated to the ionic form of the metal. 401 
Moreover, Jung el al. [109] demonstrated a higher antibacterial activity against Gram-402 
negative (E. coli) than against Gram-positive (S. aureus) bacteria. This suggests that 403 
the antibacterial activity of the metal ions might be related to the thickness of the 404 
peptidoglycan layer of Gram-positive bacteria, which may difficult the action of the 405 
silver ions at the bacterial cell membrane. An overview of the hypothesised 406 
mechanisms associated with the antibacterial activity of metal particles is presented in 407 
Figure 3. 408 
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 409 
Figure 3 – Overview of the hypothesised mechanisms associated with the antibacterial 410 
activity of metal ions. In the use of silver ions the most pronounced effects is related 411 
with cellular metabolic activity (inhibition of respiratory chain and cell pathways), as 412 
well as the generation of ROS (oxygen reactive species) and DNA and RNA damage. 413 
Diagram was modified from [111]. 414 
 415 
5. In vitro methods for antimicrobial activity evaluation 416 
A variety of screening methods can be used to evaluate in vitro antimicrobial activity 417 
of glasses and glass-ceramics. The most common are diffusion and dilution methods. 418 
The diffusion methods provide qualitative results by categorizing bacteria as 419 
susceptible, intermediate or resistant. However, cannot distinguish bacteriostatic and 420 
bactericidal. On the other hand, dilution methods are considered quantitative assays 421 
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once they determine the minimal inhibitory concentration (MIC) or/and minimum 422 
lethal concentration (MLC). 423 
Briefly, the disk-diffusion method consists in agar petri dishes inoculated with 424 
standardise inoculum of the testing microorganisms. Then, 6 mm diameter discs 425 
containing the desired concentration of the glasses are placed on the agar surface. The 426 
petri dishes are incubated under suitable conditions, where the antimicrobial agents 427 
diffuse into the agar petri dishes inhibiting the growth of the tested microorganism, 428 
and forming measurable growth zones. The disk-diffusion assay is a simple, low-cost 429 
allowing to test enormous number of microorganisms and antimicrobial agents with 430 
easy access to data analysis. 431 
On the other hand, the broth-dilution method involves preparing two-fold dilutions of 432 
the antimicrobial agent in growth medium in separated tubes. Then, each tube is 433 
inoculated with the desired inoculum at a standardized concentration. MIC can be 434 
determined by the eye. After incubation under suitable conditions for the desired time 435 
a sample from the tube can be sub-cultured on the surface of non-selective agar plates 436 
to determine the number of surviving cells (CFU/mL) after 24 h incubation, from 437 
which MLC can be determined. The broth dilution method is costly and time-438 
consuming, although allows a quantitative evaluation. 439 
Both these methods directly depend on the inoculum size and preparation, type of 440 
growth medium and incubation times. Therefore, they have been standardized by 441 
Clinical and Laboratory Standard Institute (CLSI) and European Committee in 442 
Antibacterial Susceptibility Testing (EUCAST) for testing bacteria, yeast and fungi 443 
[112-117]. However, when testing glass materials some modifications of the 444 
standardized protocols might be required. Therefore, care should be taken not to 445 
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change the basis of microbiology by altering the concentrations of media, inoculum 446 
and active glass. 447 
 448 
6. Glass and Glass-ceramics in the treatment of infectious bone defects 449 
Bacterial infections associated with contamination of implanted medical devices are a 450 
critical complication that often leads to the failure of the implant with significant 451 
impact in patient’s normal life and wellbeing. Existing treatment for MDAIs often 452 
requires local delivery of high doses of antibiotics by carrier materials such as 453 
cements, collagen sponges and calcium sulfate, which suffer from several limitations. 454 
Multifunctional BGs and glass-ceramics are an interesting alternative system that are 455 
not only effective in treating MDAIs but are also have the capacity to stimulate bone 456 
regeneration. 457 
BGs, have already shown promising results on the treatment of bone infection in 458 
humans without any signs of toxic reactions. In a clinical study, eleven patients with 459 
chronic osteomyelitis disease in the lower extremity and the spine were treated with 460 
BG S53P4, and nine of them healed without complications [118]. Moreover, the 461 
incorporation of various metal ions (i.e. Ag+, Ga2+) in BGs and glass-ceramics 462 
demonstrated the improvement of their properties towards the treatment of bone 463 
diseases. In vitro studies of the incorporation of gallium–silver into phosphate-based 464 
glasses showed to be a promising alternative to antibiotics treatments providing a 465 
controlled and local delivery of antibacterial gallium and silver ions at the site of 466 
infection in the oral cavity [91]. Another study, incorporating Ag-doped BGs into a 467 
scaffold for dental applications showed a long-lasting antibacterial activity against E. 468 
coli, E. faecalis with non-cytotoxic effects over dental pulp cells. 469 
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The bactericidal effect of the BGs and glass-ceramics is highly dependent on the 470 
design, clinical application as well as the system (material) in which it is incorporated. 471 
However, the suitable microstructural properties in addition to the bioactive and 472 
antibacterial activities of the BGs could lead to its multifunctional potential for 473 
healing and regeneration of bone and bone diseases, such as osteomyelitis or 474 
periodontitis, and change significantly the currently applied treatments. This new BGs 475 
and glass-ceramics could found important medical applications in prostheses, dental 476 
devices, coating and composite scaffold. Therefore, the use of these BG systems 477 
requires supported by preclinical model studies and creation of strong databases to 478 
track and optimise their activity towards the specific disease/condition. 479 
7. Conclusions and future outlook 480 
This review clearly demonstrates that it is possible to use inorganic modification to 481 
generate BGs and glass-ceramics into biomaterials that are capable of supressing the 482 
growth of pathogenic organisms while at the same time increasing bone tissue 483 
regeneration. This strategy offers an alternative (or at least a potent adjuvant) to 484 
antibiotics. While a number of classical glass compositions such as S53P4 and 45S5 485 
bioglass® appear to have some antimicrobial activity, there is no doubt that enhanced 486 
compositions are far more potent. For example, the addition of Ag+, Zn2+, Cu+, Ce3+ 487 
and Sr2+ all increased the antimicrobial activity of the glasses. While the presence of 488 
these specific ions has a direct effect on bacteria, it is important to note that the 489 
disruption of the glass is also influenced by small compositional changes (i.e. pH, 490 
osmolarity, particle size), which affects the degradation rate of the glass phase. It was 491 
noted that these effects were frequently neglected by authors who instead focused 492 
solely on the effects of specific ions. Therefore there is a clear need to invest in the 493 
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structural design of glass and glass-ceramics if truly innovative multifunctional 494 
systems are to be developed.  These will then provide a predictable, local delivery of 495 
antimicrobial ions to the site of infection while promoting bone tissue regeneration.  496 
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